Soumya D Chakravarty

35PUBLICATIONS
61CO-AUTHORS
AllergyPharmacogenomicsChild and adolescent developmentToxicology (incl. clinical toxicology)Rheumatology and arthritis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Feb 11, 2026
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Alexis Ogdie, Joseph F Merola, Philip J Mease

|Nov 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.

Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald

|Nov 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.

Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald

|Oct 29, 2025
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.

Herta Crauwels, Sarah Ringold, Samantha Howard

|Mar 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Alexis Ogdie, Soumya M Reddy, Sarah H Gillespie

|Dec 02, 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.

Philip J Mease, Shannon A Ferrante, Natalie J Shiff

Pageof 6

Frequent Collaborators

21 joint publications

Phillip J Mease

11 joint publications

May Shawi

6 joint publications

Atul Deodhar

6 joint publications

Christopher T Ritchlin